8-K/A: NVE Corp Extends Supplier Agreement with Abbott, Secures Price Increases
8-K/A Filing
NVE Corp extends its Supplier Partnering Agreement with Abbott Laboratories through December 31, 2025, and secures price increases for key products.
Summary
- NVE Corporation has amended its Supplier Partnering Agreement with Pacesetter, Inc. (now a subsidiary of Abbott Laboratories).
- Amendment No. 11 extends the agreement through December 31, 2025.
- The amendment includes price increases for specific parts: Part Number 1071000-001, Part Number 100101124 and Part Number 100127071.
- These price increases are effective for all shipments made after December 31, 2024.
- The amendment also introduces a new section on Trade Controls, ensuring compliance with sanctions and export/import laws.
- The agreement specifies restrictions related to Sanctioned Areas and Sanctioned Persons.
Sentiment
Score: 7
Explanation: The extension of the agreement and price increases are positive developments, suggesting a stable and profitable relationship with a key customer. However, reliance on a single customer and redacted information temper the overall sentiment.
Positives
- The extension of the Supplier Partnering Agreement provides continued revenue stream for NVE Corp.
- The price increases for key products should improve NVE Corp's profitability.
- The addition of Trade Controls demonstrates a commitment to compliance and risk management.
Risks
- Changes in trade regulations or sanctions could impact NVE Corp's ability to supply products to Abbott.
- Reliance on a single customer (Abbott) could pose a risk if the relationship were to deteriorate.
- The redacted confidential portions of the agreement could contain information that, if known, would be considered a risk.
Future Outlook
The agreement extension provides revenue visibility through December 31, 2025.
Management Comments
- Daniel A. Baker, President & CEO of NVE Corporation, signed the amendment.
Industry Context
Supplier agreements are common in the medical device industry to ensure a stable supply chain and predictable pricing. Extending these agreements is a positive sign of continued collaboration.
Comparison to Industry Standards
- Long-term supplier agreements are typical in the medical device industry, similar to agreements between Medtronic and its suppliers.
- Price increases in supplier agreements are often negotiated to reflect changes in raw material costs, labor rates, and other economic factors, similar to trends seen in contracts within the broader electronics manufacturing sector.
Stakeholder Impact
- Shareholders will likely view the agreement extension and price increases positively.
- Employees benefit from the continued stability of the company.
- Abbott benefits from a secure supply of products.
Key Dates
| Date | Description |
|---|---|
| 2006-01-01 | Effective date of the original Supplier Partnering Agreement. |
| 2007-09-06 | Effective date of Amendment No. 1. |
| 2009-12-15 | Effective date of Amendment No. 2. |
| 2010-09-13 | Effective date of Amendment No. 3. |
| 2011-02-01 | Effective date of Amendment No. 4. |
| 2016-04-20 | Effective date of Amendment No. 5. |
| 2020-12-16 | Effective date of Amendment No. 6. |
| 2021-04-12 | Effective date of Amendment No. 7. |
| 2021-11-10 | Effective date of Amendment No. 8. |
| 2022-12-05 | Effective date of Amendment No. 9. |
| 2023-12-05 | Effective date of Amendment No. 10. |
| 2024-12-17 | Amendment Effective Date of Amendment No. 11. |
| 2024-12-31 | Price increases effective for shipments made after this date. |
| 2025-01-27 | Date NVE Corporation signed Amendment No. 11. |
| 2025-02-10 | Date Pacesetter, Inc. signed Amendment No. 11. |
| 2025-12-31 | New expiration date of the Supplier Partnering Agreement. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.